Definition and Evaluation of

Similar documents
AHA/ASA Scientific Statement

Do We Need a New Definition of Stroke & TIA as Proposed by the AHA? Stroke & TIA need to Remain Clinical Diagnoses: to Change Would be Bonkers!

Evaluating ED Patients with Transient Ischemic Attack: Inpatient vs. Outpatient Strategies

ACUTE STROKE PATHWAY

THE INTERNET STROKE CENTER PRESENTATIONS AND DISCUSSIONS ON STROKE MANAGEMENT

Making the Case for CPG s Jean Luciano, MSN, RN, CNRN, SCRN, CRNP, FAHA Claranne Mathiesen, MSN, RN, CNRN, SCRN, FAHA

Level III Stroke Center Data Collection Requirements

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)

Approved: Acute Stroke Ready Hospital Advanced Certification Program

DIAGNOSTIC CRITERIA OF STROKE

Medical Management of Ischemic Stroke: An Update. Siddharth Sehgal, MD Medical Director, TMH Neuroscience Center

Stroke Coding Issues Presentation to: NorthEast Cerebrovascular Consortium

Vertebrobasilar Disease

Main Effect of Screening for Coronary Artery Disease Using CT

Imaging of Acute Stroke. Noam Eshkar, M.D New Jersey Neuroscience Institute JFK Medical Center Edison Radiology Group

What Is an Arteriovenous Malformation (AVM)?

ALBERTA PROVINCIAL STROKE STRATEGY (APSS)

Long term care coding issues for ICD-10-CM

Department of Veterans Affairs VHA DIRECTIVE Veterans Health Administration Washington, DC November 2, 2011

AHA/ASA Scientific Statement

Renovascular Hypertension

Perioperative Cardiac Evaluation

DISCLOSURES RISK ASSESSMENT. Stroke and Heart Disease -Is there a Link Beyond Risk Factors? Daniel Lackland, MD

What You Should Know About Cerebral Aneurysms

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY

PHYSICIAN ORDERS TRANSIENT ISCHEMIC ATTACK (TIA) OBSERVATION

Listen to your heart: Good Cardiovascular Health for Life

CASE SELECTION: EVALUATING THE RECORDS TO DETERMINE WHICH CASES TO REJECT OR TAKE

STROKE PREVENTION AND TREATMENT MARK FISHER, MD PROFESSOR OF NEUROLOGY UC IRVINE

Stuart B Black MD, FAAN Chief of Neurology Co-Medical Director: Neuroscience Center Baylor University Medical Center at Dallas

Lifecheque Basic Critical Illness Insurance

doi: /j.jocn

CARDIAC CARE. Giving you every advantage

CERTIFICATE OF NEED AND ACUTE CARE LICENSURE PROGRAM. Hospital Licensing Standards: Emergency Department and Trauma Services:

OHTAC Recommendation

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

Christopher M. Wright, MD, MBA Pioneer Cardiovascular Consultants Tempe, Arizona

Accreditation and Certification Guidelines

Atherosclerosis of the aorta. Artur Evangelista

Your Guide to Express Critical Illness Insurance Definitions

ESC/EASD Pocket Guidelines Diabetes, pre-diabetes and cardiovascular disease

Appendix L: HQO Year 1 Implementation Priorities

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Coronary Artery Disease leading cause of morbidity & mortality in industrialised nations.

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Secondary Stroke Prevention Luke Bradbury, MD 10/4/14 Fall WAPA Conferfence

Treating AF: The Newest Recommendations. CardioCase presentation. Ethel s Case. Wayne Warnica, MD, FACC, FACP, FRCPC

Stroke Prevention in Primary Care

Understanding the Pain Trajectory During Treadmill Testing in Peripheral Artery Disease

A stroke occurs when blood flow to the brain is blocked (called ischemic stroke). This is caused by one of the following:

NCD for Lipids Testing

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) DRAFT GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

Steps to getting a diagnosis: Finding out if it s Alzheimer s Disease.

2007 CMS Physician Quality Reporting Initiative (PQRI) Guidance for Reporting

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

Stroke: Major Public Health Burden. Stroke: Major Public Health Burden. Stroke: Major Public Health Burden 5/21/2012

STATEMENT OF STANDARD

Hot Topics: Current PFO Recommendations and Loop Monitoring/Cryptogenic Stroke.

2.1 Who first described NMO?

GP workshop. Maria Fitzpatrick Nurse Consultant Kings College Stroke Centre

Advances in Stroke Care

American Stroke Association Highlights Carla D. English, MHS, MHSA

APPENDIX A NEUROLOGIST S GUIDE TO USING ICD-9-CM CODES FOR CEREBROVASCULAR DISEASES INTRODUCTION

Therapeutic Management Options for. Acute Ischemic Stroke Anna Rosenbaum, MD

NAME OF THE HOSPITAL: 1. Coronary Balloon Angioplasty: M7F1.1/ Angioplasty with Stent(PTCA with Stent): M7F1.3

4th Annual New York Stroke Conference Maximizing Stroke Quality of Care: Key Ingredients

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE EVALUATION OF MEDICINAL PRODUCTS FOR CARDIOVASCULAR DISEASE PREVENTION

STROKE AND TIA MULTIDISCIPLINARY CARE PATHWAY 6 th Edition Cornwall Stroke Service (Royal Cornwall Hospital Trust Facing)

Treatments to Restore Normal Rhythm

PHARMACOLOGICAL Stroke Prevention in Atrial Fibrillation STROKE RISK ASSESSMENT SCORES Vs. BLEEDING RISK ASSESSMENT SCORES.

Evidence-Based Secondary Stroke Prevention and Adherence to Guidelines

Summary Diagnosis and Treatment of Chronic Cerebrospinal Venous Insufficiency (CCSVI) in People with Multiple Sclerosis (MS)

Developing a Dynamic Team Approach to Stroke Care. Emergency Medical Services 2015

Atrial Fibrillation, Chronic - Antithrombotic Treatment - OBSOLETE

Cardiovascular Endpoints

Sample Treatment Protocol

Cavernous Angioma. Cerebral Cavernous Malformation ...

Spontaneous Vertebral Artery Dissection. William Barsan, MD, FACEP

Helen Fry Manager, Publications and Education Resources Joint Commission Resources

ADULT HEALTH AND WELLBEING LONG-TERM NEUROLOGICAL CONDITIONS

CARDIOLOGY ROTATION GOALS AND OBJECTIVES

ß-interferon and. ABN Guidelines for 2007 Treatment of Multiple Sclerosis with. Glatiramer Acetate

Chapter 4 Health Care Management Unit 1: Care Management

A dissertation submitted for the Degree of Doctor of Medicine of the University of Cambridge. November 2011

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244

Is this pt s brain dysfunction due to ischemia? Onset & progression of sx; location of deficit

Future Generali India Life Insurance Company Limited. Registration No. 133

CHAPTER 4 QUALITY ASSURANCE AND TEST VALIDATION

EXHIBIT H SETTLEMENT ELIGIBILITY CRITERIA. a) pharmacy records reflecting the dispensing of Bextra and/or Celebrex to the Class Member; or

Brooklyn Stroke Symposium 2015

Attack Care Bundle. Emergency Department Stroke and Transient Ischaemic. Summary for clinicians

AUBMC Multiple Sclerosis Center

Systolic Blood Pressure Intervention Trial (SPRINT) Principal Results

Mellen Center for Multiple Sclerosis

09/05/2014. Painting pictures of the brain with numbers. Overview

AHA/ASA Ischemic Stroke Performance Measures

6/3/2011. High Prevalence and Incidence. Low back pain is 5 th most common reason for all physician office visits in the U.S.

Transcription:

The American Academy of Neurology (AAN) affirms the value of this paper as an educational tool for neurologists. Definition and Evaluation of Transient Ischemic Attack A Scientific Statement for Health Care Professionals from the American Heart Association/American Stroke Association Stroke Council, the Cardiovascular Surgery and Anesthesia Council, the Cardiovascular Radiology and Intervention Council, and the Cardiovascular Nursing Council and the Atherosclerotic Peripheral Vascular Disease Working Group J. Donald Easton, MD, FAHA, Chair; Jeffrey Saver, MD, FAHA, Vice Chair; Gregory W. Albers, MD; Mark J. Alberts, MD, FAHA; Seemant Chaturvedi, MD, FAHA, FAAN; Edward Feldmann, MD, FAHA; Thomas S. Hatsukami, MD; Randall Higashida, MD, FAHA; S. Claiborne Johnston, MD, PhD; Chelsea S. Kidwell, MD, FAHA; Helmi Lutsep, MD; Elaine Miller, DNS, RN, CRRN, FAHA; Ralph L. Sacco, MD, MS, FAAN, FAHA Definition and Evaluation of Transient Ischemic Attack slides Edited by Ramesh Madhavan MD, DM. Dawn Kleindorfer MD. Members, AHA Professional Education Committee

OBJECTIVE The Scientific statement is designed to aid the clinician in understanding the acute and long term management of patients with Transient Ischemic Attack will present the early risk of stroke and other vascular outcomes associated with TIA Topics reviewed: Definitions of TIA Urgency for early management. Evaluation of TIA EPIDEMIOLOGY INCIDENCE AND PREVALENCE Estimated incidence of TIA in United States - around 200,000 to 500,000/ year; Population prevalence -2.3% ( five million individuals). 1,2 Limitations: Precise estimates of the incidence and prevalence of TIAs are difficult to determine due to the varying criteria used in epidemiological studies to identify TIA lack of recognition of the transitory symptoms may also lead to gross underestimates. 1.Johnston SC. N Engl J Med. 2002;347(21):1687-1692. 1692. 2.Johnston SC et al., Neurology. 2003;60(9):1429-1434. 1434. EPIDEMIOLOGY VARIATIONS DUE TO AGE AND RACE-ETHNICITY ETHNICITY TIA incidence markedly increases with age and varies by race-ethnicity. ethnicity. TIA prevalence rates vary depending on the age distribution of the study population. VARIATIONS IN DIAGNOSIS Variability in the utilization of brain imaging and the type of diagnostic imaging markedly affects estimates of the incidence and prevalence of TIAs.

EPIDEMIOLOGY PREVALENCE OF PRIOR TIA IN PATIENTS WITH STROKE Prevalence of prior TIA ranges from 7% to 40%, among patients who present with stroke. 11,12 Percentage varies depending on how TIA is defined stroke subtypes are evaluated, and whether the study is a population-based series or a hospital-based series 11.Dennis M et al., Stroke. 1990;21(6):848-853. 853. 12.Bogousslavsky J et al., Stroke. 1988;19(9):1083-1092. 1092. DEFINITION Traditional definition: TIAs were operationally defined as any focal cerebral ischemic event with symptoms lasting less than 24 hours. New tissue-based, rather than time-based, definition proposed in 2002. 20 a brief episode of neurological dysfunction caused by focal brain or retinal ischemia, with clinical symptoms typically lasting less than one hour, and without evidence of acute infarction. 20.Albers GW et al., N Engl J Med. 2002;347(21):1713-1716. 1716. Arguments in favor of the new definition 1. A 24-hour duration of symptoms does not accurately demarcate patients with and without tissue infarction (Class III, Level of Evidence A). The 24-symptom duration rule misclassifies up to one-third of patients who have actually experienced underlying tissue infarction as not having suffered tissue injury.

Arguments in favor of the new definition 2. 24-hour maximum duration has the potential to delay the initiation of effective stroke therapies (Class I, Level of Evidence C). Patients with deficits lasting one hour or more are highly likely to develop permanent deficits unless an effective therapy is initiated. 3. The frequency distribution of durations of transiently symptomatic cerebral ischemic events shows no special relationship to the 24-hour time point (Class III, Level of Evidence A). Consideration of symptom durations alone, regardless of association with underlying tissue injury, provides no indication that the 24-hour time point is of any special significance. Arguments in favor of the new definition 4. A tissue-based definition of TIA will direct diagnostic attention to identifying the cause of ischemia and whether brain injury occurred (Class IIa, Level of Evidence C). Tissue-based definitions are the rule for ischemic injuries affecting other end organs. For example, distinguishing angina from myocardial infarction A tissue-based definition of TIA encourages use of neuro diagnostic tests to identify brain injury and its vascular genesis. Arguments against the new definition 1. Diagnostic tests play a key role to identify if there is evidence of brain infarction. This will vary depending on the availability of imaging resources. Imaging currently plays a central role in both determining the etiology of, and classifying, acute cerebrovascular syndromes (Class I, Level of Evidence A) 2. The new definition will modestly alter stroke and TIA prevalence and incidence rates,, but these changes are to be encouraged, as they reflect increasing accuracy of diagnosis (Class IIa, Level of Evidence C).

Arguments against the new definition 3. Primary care physicians may be confused, whether to designate a presumed transient event of brain ischemia a stroke or TIA if they do not have immediate access to neuro imaging or other diagnostic resources 4. cerebral infarction with transient symptoms (CITS) or transient symptoms with infarction (TSI) suggested to describe events that last < 24 hours but are associated with cerebral infarction, retaining the 24- hour time threshold in syndrome definition. However, there is no evidence to support incorporation of any particular time criterion for CITS or TSI. Arguments against the new definition 5. The one- hour time point, like the 24-hour time point, does not accurately distinguish between patients with or without acute cerebral infarction. It is impossible to define a specific time cut-off that can distinguish whether a symptomatic ischemic event will result in brain injury with high sensitivity and specificity (Class III, Level of Evidence A). AHA-Endorsed Revised Definition of TIA Transient ischemic attack (TIA): a transient episode of neurological dysfunction caused by focal brain, spinal cord, or retinal ischemia, without acute infarction. The Writing Committee found that the key elements of the 2002 Working Group s s proposed definition are well supported by the data in the literature. However, the reference to a one-hour time point was not helpful, as the one-hour time point does not demarcate events with and without tissue infarction.

URGENCY SHORT TERM STROKE RISK: Most studies find risks of stroke exceeding 10% in 90 days after TIA. 4, 11, 19, 50-59 59 One-quarter to one-half of strokes that occur within three months occur within the first two days. 11, 19, 50, 54, 57, 59, 60 Ischemic stroke carries a lower three-month risk of subsequent ischemic stroke ranging from 4% to 8%. 54-56, 58 Risk of cardiac events is also elevated after TIA. These findings underscore the need for prompt evaluation and treatment of patients with symptoms of ischemia. RISK STRATIFICATION The California score and the ABCD score both predict short-term term risk of stroke well in independent populations of patients presenting acutely after a TIA. 64 The newer ABCD 2 score provides a more robust prediction standard and incorporates elements from both the prior scores. 64 MRI changes have been associated with the clinical factors identified in prior prediction rules, 34 so it is unclear how much they will add to validated prediction rules, such as ABCD 2. ABCD 2 SCORE SCORE 1 Age 60 years FACTORS 1 Blood pressure >140/90 mmhg on first evaluation 2 1 Clinical symptoms of focal weakness with the spell (or) speech impairment without weakness 2 1 Duration > 60 minutes (or) 10 to 59 minutes 1 Diabetes

STROKE RISK USING ABCD 2 SCORE Two-day risk of stroke in combined validation cohorts ABCD 2 SCORE STROKE RISK 0-1 0% 2-3 1.3% 4-5 4.1% 6-7 8.1% No randomized trial has evaluated the utility of the ABCD 2 score in assisting with triage decisions HOSPITALIZATION Hospitalization rates after TIA vary widely among practitioners, hospitals, and regions Close observation during hospitalization has the potential to allow more rapid and frequent administration of tpa should a stroke occur. Other benefits: cardiac monitoring, rapid diagnostic evaluation, greater rates of adherence to secondary prevention interventions. 68 No randomized trial has evaluated the benefit of hospitalization DIAGNOSTIC EVALUATION MRI, including diffusion sequences, should be considered a preferred diagnostic test in the investigation of the patient with potential TIAs. MRI permits confirmation of focal ischemia as the cause of a patient s s deficit, improves accuracy of diagnosis of the vascular localization and etiology of TIA, and assesses the extent of pre-existing existing cerebrovascular injury. Vessel imaging, cardiac evaluation, and laboratory testing, should be completed according to the AHA acute stroke guidelines. 69

CLASS I RECOMMENDATIONS 1. Patients with TIA should preferably undergo neuroimaging evaluation within 24 hours of symptom onset. MRI, including DWI,, is the preferred brain diagnostic imaging modality. If MRI is not available, head CT should be performed (Class I, Level of Evidence B). 2. Noninvasive imaging of the cervicocephalic vessels should be performed routinely as part of the evaluation of patients with suspected TIAs (Class I, Level of Evidence A). CLASS I RECOMMENDATIONS 3. Noninvasive testing of the intracranial vasculature reliably excludes the presence of intracranial stenosis (Class I, Level of Evidence A) and is reasonable to obtain when knowledge of intracranial steno-occlusive occlusive disease will alter management. Reliable diagnosis of the presence and degree of intracranial stenosis requires the performance of catheter angiography to confirm abnormalities detected with noninvasive testing. 4. Patients with suspected TIA should be evaluated as soon as possible after an event (Class I, Level of Evidence B). CLASS II RECOMMENDATIONS 1. Initial assessment of the extracranial vasculature may involve any of the following: carotid ultrasound/tcd, MRA or CTA, depending on local availability and expertise, and characteristics of the patient (Class IIa, Level of Evidence B). 2. If only noninvasive testing is performed prior to endarterectomy, it is reasonable to pursue two concordant noninvasive findings; otherwise catheter angiography should be considered (Class IIa, Level of Evidence B).

CLASS II RECOMMENDATIONS 3. The role of plaque characteristics and detection of microembolic signals is not yet defined (Class IIb, Level of Evidence B). 4. Electrocardiography should occur as soon as possible after TIA (Class I, Level of Evidence B). Prolonged cardiac monitoring (inpatient telemetry or Holter monitor) is useful in patients with an unclear etiology after initial brain imaging and electrocardiography (Class IIa, Level of Evidence B). CLASS II RECOMMENDATIONS 5. Echocardiography (at least TTE) is reasonable in the evaluation of patients with suspected TIAs, especially when the patient has no cause is identified by other elements of the work-up (Class IIa, Level of Evidence B). TEE is useful in identifying patent foramen ovale, aortic arch atherosclerosis, and valvular disease and is reasonable when identification of these conditions will alter management (Class IIa, Level of Evidence B). 6. Routine blood tests (complete blood count, chemistry panel, prothrombin time and partial thromboplastin time, and fasting lipid panel) are reasonable in the evaluation of patients with suspected TIAs (Class IIa, Level of Evidence B). CLASS II RECOMMENDATIONS 7. It is reasonable to hospitalize patients with TIA if they present within 72 hours of the event and any of the following criteria are present: ABCD 2 score of 3, (Class IIa, Level of Evidence C). ABCD 2 score of 0-20 2 and uncertainty that diagnostic work-up can be completed within 2 days as an outpatient (Class IIa, Level of Evidence C). ABCD 2 score of 0-20 2 and there is other evidence that indicates the patient s s event was caused by focal ischemia (Class IIa, Level of Evidence C).

Optional coagulation screening tests In younger patients with TIAs, particularly when no vascular risk factors exist and no underlying etiology is identified